In a bid to pull the curtain back on drug pricing, Senator Ron Wyden (D-Ore.) introduced a bill Wednesday that would require pharmacy benefit managers to disclose information about the controversial rebates paid by drug makers to win coveted spots on health plan formularies.

The legislation would force pharmacy benefit managers, which are the middlemen that negotiate prices between drug makers and health plans, to publicly post aggregated data about rebates and discounts that are obtained on behalf of Medicare Part D and Medicare Advantage plans.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy